QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Rare disease HTA: TLV accepts an ICER above 2 million SEK/QALY
TLV’s recent decision on Fabhalta provides further evidence of how Sweden applies higher acceptable ICERs in very rare conditions.
Fabhalta was assessed for a very rare, severe chronic kidney disease population. Following three-party negotiations, TLV’s base case, including the confidential agreement, resulted in:
➡️ ICER: 2,035,738 SEK/QALY
➡️ QALY gain: 3.91
➡️ Rarity index: 56–85
➡️ Outcome: reimbursement with restriction
You can read the official decision here
And the full HTA report here
Why is […]
TLV postpones guideline updates
The Swedish HTA agency TLV has announced changes to the timeline and content of its upcoming guidance on reimbursement and pricing of medicines.
Key points from the update:
📍The previously communicated timeline has been postponed. The revised guidance will enter into force on October 1, 2026
📍The original proposed model for systematic price reductions linked to sales volumes will not be included. Nonetheless, TLV states that sales volumes will be considered in […]
🟢Day 2- beyond pharmacoeconomics
Day 2 at SHEA highlighted a broader perspective: health economics extends well beyond traditional pharmacoeconomic frameworks.
Discussions included applications across:
📍social care alongside healthcare
📍the health economic value of green outdoor environments
Closer to our core areas, two themes stood out:
➡️ the continued importance of Nordic registries and their wide applicability
➡️ evolving methods to expand data inputs in health economic evaluations
A presentation by Professor Mikael Svensson also highlighted collaborative research efforts, including contributions […]
🔹SHEA Day 1 – Navigating HTA under pressure
Day 1 in Lund highlighted a clear direction: global policy shifts are increasingly shaping local HTA realities.
External changes, including US MFN policy, are already influencing the pharmaceutical landscape beyond their origin.
Less than a year on, the impact feels well embedded.
At the same time, innovation is shifting toward more specialised therapies.
This is adding pressure to value-based pricing frameworks and challenging established standards.
As highlighted by keynote speaker Amanda Cole, innovative payment […]
